oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease SOUL: Oral Semaglutide Bests Usual

A recent study published in Diabetes Obesity and Metabolism found that individuals using these medications lost significant amounts of fat but also experienced some degree of muscle loss, with lean body mass reductions making up approximately 25%40% of total weight Trusted Source Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Neeland IJ, Linge J, Birkenfeld AL Go to Source loss

The KDIGO guidelines recommend phasing out the term micro-albuminuria and replacing it with the term albuminuria

This delayed gastric emptying is central to semaglutide's appetite-suppressing effects but can also contribute to reduced food intake

Nutritional status: Long-term semaglutide use requires attention to nutritional adequacy

Some people experience very mild symptoms or none at all, while others may notice more pronounced effects, particularly during early treatment or dose increases